Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs.
暂无分享,去创建一个
[1] B. Gabryel,et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide , 2010, Pharmacological reports : PR.
[2] Anna Seelig,et al. Quantification and characterization of P-glycoprotein-substrate interactions. , 2006, Biochemistry.
[3] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[4] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[5] A. Hill,et al. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.
[6] Li Di,et al. Drug-like property concepts in pharmaceutical design. , 2009, Current pharmaceutical design.
[7] Patrick E. Trapa,et al. Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling , 2012, Expert opinion on drug metabolism & toxicology.
[8] Anthony A Estrada,et al. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. , 2015, Journal of medicinal chemistry.
[9] J J Baldwin,et al. Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.
[10] Z. Rankovic,et al. CNS drug design: balancing physicochemical properties for optimal brain exposure. , 2015, Journal of medicinal chemistry.
[11] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[12] Yaxiong Sun,et al. De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds. , 2013, ACS medicinal chemistry letters.
[13] D. Kyle,et al. Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.